Answers are grounded in this paper and cite their sources.
The benefit of adding chemotherapy to first-line epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in advanced EGFR-mutated non–small-cell lung cancer (NSCLC) remains uncertain. We evaluated the efficacy and safety of EGFR-TKI plus chemotherapy versus EGFR-TKI monotherapy. PubMed, Embase, and the Cochrane Library were searched from inception to August 2026 for randomized controlled trials (RCTs) comparing first-line EGFR-TKI plus chemotherapy with EGFR-TKI monotherapy in adults with advanced EGFR-mutated NSCLC. Random-effects models were used to pool hazard ratios (HRs) and risk ratios (RRs) with 95% CIs. Subgroup, sensitivity, trial sequential analysis, and GRADE assessments were performed. Seven RCTs involving 2454 patients were included. Combination therapy significantly improved overall survival (HR: 0.64; 95% CI: 0.53-0.77) and progression-free survival (HR: 0.54; 95% CI: 0.45-0.64) compared with EGFR-TKI monotherapy. Objective response rate was also higher with combination therapy (RR: 1.14; 95% CI: 1.07-1.20). However, combination therapy substantially increased treatment-related toxicity, particularly grade ≥3 and hematologic adverse events. Sensitivity analyses supported the robustness of the primary efficacy findings. Subgroup analyses demonstrated consistent OS and PFS benefits across EGFR-TKI generations. Adding chemotherapy to first-line EGFR-TKI therapy improves survival and tumor response in advanced EGFR-mutated NSCLC but increases treatment-related toxicity. These findings support combination therapy while highlighting the need to balance clinical benefit against treatment burden.
No takes yet. Share an insight, caveat, or question.
Khalid et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: